SeeThruEquity Initiates Research Coverage on Cardax, Inc. with a Target Price of $1.00
ACCESSWIRE - Mon Oct 06, 8:06AM CDT
New York, NY / ACCESSWIRE / October 6, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Cardax, Inc. (OTCQB: CDXI), Cardax is a development stage, life sciences company focused on introducing nutraceutical and pharmaceutical products aimed at reducing inflammation and oxidative stress.
Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors
Business Wire - Tue Jun 17, 7:01AM CDT
Cardax, Inc. ("Cardax"
OXGN: 1.39 (-0.02), ACT: 295.76 (-0.84), LXRX: 1.01 (unch), ONVO: 4.48 (-0.06), BMY: 68.00 (+0.36), NVS: 104.06 (+0.31)